Pfizer Inc. $PFE Holdings Boosted by Prospector Partners LLC

Prospector Partners LLC boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 60.9% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 142,455 shares of the biopharmaceutical company's stock after acquiring an additional 53,900 shares during the period. Prospector Partners LLC's holdings in Pfizer were worth $3,610,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of PFE. William B. Walkup & Associates Inc. raised its holdings in shares of Pfizer by 1.2% during the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after buying an additional 454 shares during the last quarter. Members Trust Co raised its holdings in shares of Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after buying an additional 467 shares during the last quarter. Sutton Place Investors LLC raised its holdings in shares of Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after buying an additional 472 shares during the last quarter. Bellevue Group AG raised its holdings in shares of Pfizer by 0.3% during the fourth quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock valued at $3,756,000 after buying an additional 485 shares during the last quarter. Finally, MSH Capital Advisors LLC raised its holdings in shares of Pfizer by 1.4% during the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company's stock valued at $876,000 after buying an additional 485 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 0.2%

Pfizer stock opened at $25.16 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market cap of $143.05 billion, a price-to-earnings ratio of 13.38, a price-to-earnings-growth ratio of 0.89 and a beta of 0.52. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The firm's 50 day moving average price is $24.60 and its two-hundred day moving average price is $24.42.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the business posted $0.60 EPS. The company's revenue was up 10.3% on a year-over-year basis. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on PFE shares. The Goldman Sachs Group lifted their price target on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Bank of America lifted their price target on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Cantor Fitzgerald assumed coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Wolfe Research raised their price objective on shares of Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a research note on Wednesday, April 30th. Finally, UBS Group raised their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.